{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T23:43:29Z","timestamp":1792107809902,"version":"4.4.0"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2020,11,11]],"date-time":"2020-11-11T00:00:00Z","timestamp":1605052800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"GlaxoSmithKline Biologicals SA","award":["HO-19-19880"],"award-info":[{"award-number":["HO-19-19880"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,12,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Despite the burden of varicella, there is no universal varicella vaccination (UVV) program in the United Kingdom (UK) due to concerns that it could increase herpes zoster (HZ) incidence. We assessed the cost-utility of a first-dose monovalent (varicella [V]) or quadrivalent (measles-mumps-rubella-varicella [MMRV]) followed by a second-dose MMRV UVV program. GSK and MSD varicella-containing vaccines (VCVs) were considered.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Dynamic transmission and cost-effectiveness models were adapted to the UK. Outcomes measured included varicella and HZ incidences and the incremental cost-utility ratio (ICURs) over a lifetime horizon. Payer and societal perspectives were evaluated.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The impact of V-MMRV and MMRV-MMRV UVV programs on varicella incidence was comparable between both VCVs at equilibrium. HZ incidence increased by 1.6%\u20131.7% over 7 years after UVV start, regardless of the strategies, then decreased by &amp;gt;95% at equilibrium. ICURs ranged from \u00a35665 (100 years) to \u00a318 513 (20 years) per quality-adjusted life-year (QALY) gained with V-MMRV and from \u00a39220 to \u00a327 101 per QALY gained with MMRV-MMRV (payer perspective). MMRV-MMRV was cost-effective in the medium- and long-terms with GSK VCV and only cost-effective in the long term with MSD VCV at a \u00a320 000 per QALY gained threshold. Without the exogenous boosting hypothesis, HZ incidence decreased through UVV implementation. ICURs were most sensitive to discount rates and MMRV price.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>A 2-dose UVV was demonstrated to be a cost-effective alternative to no vaccination. With comparable effectiveness as MSD VCV at lower costs, GSK VCV may offer higher value for the money.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/cid\/ciaa1708","type":"journal-article","created":{"date-parts":[[2020,11,5]],"date-time":"2020-11-05T12:40:31Z","timestamp":1604580031000},"page":"e3617-e3626","source":"Crossref","is-referenced-by-count":20,"title":["Epidemiological Impact and Cost-Effectiveness of Varicella Vaccination Strategies in the United Kingdom"],"prefix":"10.1093","volume":"73","author":[{"given":"Esse Ifebi Herve","family":"Akpo","sequence":"first","affiliation":[{"name":"Vaccines, GSK, Wavre, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7434-4349","authenticated-orcid":false,"given":"Olivier","family":"Cristeau","sequence":"additional","affiliation":[{"name":"Health economics and outcomes, Creativ Ceutical, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8717-6153","authenticated-orcid":false,"given":"Manjit","family":"Hunjan","sequence":"additional","affiliation":[{"name":"Vaccines, GSK, Uxbridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Casabona","sequence":"additional","affiliation":[{"name":"Vaccines, GSK, Wavre, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,11,11]]},"reference":[{"key":"2021121022364937000_CIT0001","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1017\/S0950268817001546","article-title":"A systematic review of varicella seroprevalence in European countries before universal childhood immunization: deriving incidence from seroprevalence data","volume":"145","author":"Bollaerts","year":"2017","journal-title":"Epidemiol Infect"},{"key":"2021121022364937000_CIT0002","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1186\/s12879-017-2445-2","article-title":"Estimation of the burden of varicella in Europe before the introduction of universal childhood immunization","volume":"17","author":"Riera-Montes","year":"2017","journal-title":"BMC Infect Dis"},{"key":"2021121022364937000_CIT0003","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jinf.2016.05.008","article-title":"The burden of hospitalisation for varicella and herpes zoster in England from 2004 to 2013","volume":"73","author":"Hobbelen","year":"2016","journal-title":"J Infect"},{"key":"2021121022364937000_CIT0004","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1080\/14760584.2017.1343669","article-title":"Varicella vaccination\u2014the global experience","volume":"16","author":"Wutzler","year":"2017","journal-title":"Expert Rev Vaccines"},{"key":"2021121022364937000_CIT0005","author":"Service"},{"key":"2021121022364937000_CIT0006","author":"Immunisation JCoVa"},{"key":"2021121022364937000_CIT0007","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/j.vaccine.2011.11.026","article-title":"The cost-effectiveness of varicella and combined varicella and herpes zoster vaccination programmes in the United Kingdom","volume":"30","author":"van Hoek","year":"2012","journal-title":"Vaccine"},{"key":"2021121022364937000_CIT0008","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1136\/adc.88.10.862","article-title":"Varicella vaccination in England and Wales: cost-utility analysis","volume":"88","author":"Brisson","year":"2003","journal-title":"Arch Dis Child"},{"key":"2021121022364937000_CIT0009","first-page":"9","article-title":"The nature of herpes zoster: a long-term study and a new hypothesis","volume":"58","author":"Hope-Simpson","year":"1965","journal-title":"Proc R Soc Med"},{"key":"2021121022364937000_CIT0010","first-page":"S13","article-title":"Herpes zoster pathogenesis and cell-mediated immunity and immunosenescence","volume":"109","author":"Oxman","year":"2009","journal-title":"J Am Osteopath Assoc"},{"key":"2021121022364937000_CIT0011","doi-asserted-by":"crossref","first-page":"7072","DOI":"10.1016\/j.vaccine.2018.09.013","article-title":"Herpes zoster in the context of varicella vaccination\u2014an equation with several variables","volume":"36","author":"Wutzler","year":"2018","journal-title":"Vaccine"},{"key":"2021121022364937000_CIT0012","doi-asserted-by":"crossref","first-page":"e004833","DOI":"10.1136\/bmjopen-2014-004833","article-title":"Systematic review of incidence and complications of herpes zoster: towards a global perspective","volume":"4","author":"Kawai","year":"2014","journal-title":"BMJ Open"},{"key":"2021121022364937000_CIT0013","doi-asserted-by":"crossref","first-page":"3385","DOI":"10.1016\/j.vaccine.2010.02.079","article-title":"Modeling the impact of one- and two-dose varicella vaccination on the epidemiology of varicella and zoster","volume":"28","author":"Brisson","year":"2010","journal-title":"Vaccine"},{"key":"2021121022364937000_CIT0014","doi-asserted-by":"crossref","first-page":"e60732","DOI":"10.1371\/journal.pone.0060732","article-title":"Perspectives on the impact of varicella immunization on herpes zoster. A model-based evaluation from three European countries","volume":"8","author":"Poletti","year":"2013","journal-title":"PLoS One"},{"key":"2021121022364937000_CIT0015","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1093\/infdis\/jiy642","article-title":"The Hope-Simpson hypothesis and its implications regarding an effect of routine varicella vaccination on herpes zoster incidence","volume":"219","author":"Finn","year":"2018","journal-title":"J Infect Dis"},{"key":"2021121022364937000_CIT0016","article-title":"Childhood vaccination coverage statistics\u2014England 2017\u201318","author":"Service","year":"2018"},{"key":"2021121022364937000_CIT0017","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/jpids\/piu081","article-title":"Safety and immunogenicity of human serum albumin-free MMR vaccine in US children aged 12-15 months","volume":"4","author":"Mufson","year":"2015","journal-title":"J Pediatric Infect Dis Soc"},{"key":"2021121022364937000_CIT0018","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s12887-019-1425-7","article-title":"Safety and immunogenicity of a varicella vaccine without human serum albumin (HSA) versus a HSA-containing formulation administered in the second year of life: a phase III, double-blind, randomized study","volume":"19","author":"Faust","year":"2019","journal-title":"BMC Pediatr"},{"key":"2021121022364937000_CIT0019","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1093\/jpids\/piz010","article-title":"Immunogenicity and safety of a measles-mumps-rubella vaccine administered as a first dose to children aged 12 to 15 months: a phase III, randomized, noninferiority, lot-to-lot consistency study","volume":"9","author":"Klein","year":"2019","journal-title":"J Pediatric Infect Dis Soc"},{"key":"2021121022364937000_CIT0020","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S1473-3099(18)30716-3","article-title":"Protection against varicella with two doses of combined measles-mumps-rubella-varicella vaccine or one dose of monovalent varicella vaccine: 10-year follow-up of a phase 3 multicentre, observer-blind, randomised, controlled trial","volume":"19","author":"Povey","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"2021121022364937000_CIT0021","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/01.inf.0000109287.97518.67","article-title":"Ten year follow-up of healthy children who received one or two injections of varicella vaccine","volume":"23","author":"Kuter","year":"2004","journal-title":"Pediatr Infect Dis J"},{"key":"2021121022364937000_CIT0022","doi-asserted-by":"crossref","first-page":"3411","DOI":"10.1002\/sim.1268","article-title":"Use of statistical models for evaluating antibody response as a correlate of protection against varicella","volume":"21","author":"Chan","year":"2002","journal-title":"Stat Med"},{"key":"2021121022364937000_CIT0023","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.vaccine.2017.11.042","article-title":"Measuring the cost of a pediatric vaccine administration in the UK","volume":"36","author":"Mokiou","year":"2018","journal-title":"Vaccine"},{"key":"2021121022364937000_CIT0024","doi-asserted-by":"crossref","first-page":"3636","DOI":"10.1016\/j.vaccine.2015.06.009","article-title":"Risk of febrile seizure after measles-mumps-rubella-varicella vaccine: a systematic review and meta-analysis","volume":"33","author":"Ma","year":"2015","journal-title":"Vaccine"},{"key":"2021121022364937000_CIT0025","doi-asserted-by":"crossref","first-page":"e025553","DOI":"10.1136\/bmjopen-2018-025553","article-title":"Public health impact model estimating the impact of introducing an adjuvanted recombinant zoster vaccine into the UK universal mass vaccination programme (to be published)","volume":"9","author":"Van Oorschot","year":"2019","journal-title":"BMJ Open"},{"key":"2021121022364937000_CIT0026","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s12916-018-1094-7","article-title":"The impact of demographic changes, exogenous boosting and new vaccination policies on varicella and herpes zoster in Italy: a modelling and cost-effectiveness study","volume":"16","author":"Melegaro","year":"2018","journal-title":"BMC Med"},{"key":"2021121022364937000_CIT0027","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMp048320","article-title":"Varicella vaccine and infection with varicella-zoster virus","volume":"352","author":"V\u00e1zquez","year":"2005","journal-title":"N Engl J Med"},{"key":"2021121022364937000_CIT0028","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2165\/00019053-200321010-00002","article-title":"Economic evaluations of varicella vaccination programmes: a review of the literature","volume":"21","author":"Thiry","year":"2003","journal-title":"Pharmacoeconomics"},{"key":"2021121022364937000_CIT0029","doi-asserted-by":"crossref","first-page":"S372","DOI":"10.1016\/j.jval.2018.09.2221","article-title":"PRM100\u2014weighted method for estimating incidence of herpes zoster in the general population","volume":"21","author":"Hunjan","year":"2018","journal-title":"Value Health"},{"key":"2021121022364937000_CIT0030","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.1016\/S0264-410X(02)00245-1","article-title":"A comparison of safety, tolerability and immunogenicity of Oka\/Merck varicella vaccine and VARILRIX in healthy children","volume":"20","author":"Lau","year":"2002","journal-title":"Vaccine"},{"key":"2021121022364937000_CIT0031","doi-asserted-by":"crossref","first-page":"e20153741","DOI":"10.1542\/peds.2015-3741","article-title":"Global varicella vaccine effectiveness: a meta-analysis","volume":"137","author":"Marin","year":"2016","journal-title":"Pediatrics"},{"key":"2021121022364937000_CIT0032","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1186\/s12889-016-3738-x","article-title":"Coverage, efficacy or dosing interval: which factor predominantly influences the impact of routine childhood vaccination for the prevention of varicella? A model-based study for Italy","volume":"16","author":"Holl","year":"2016","journal-title":"BMC Public Health"},{"key":"2021121022364937000_CIT0033","doi-asserted-by":"crossref","first-page":"5402","DOI":"10.1016\/j.vaccine.2017.07.051","article-title":"MMR and MMRV vaccines","volume":"36","author":"Kowalzik","year":"2018","journal-title":"Vaccine"},{"key":"2021121022364937000_CIT0034","author":"Ministero della Salute - Vaccinazioni. Salute Md"},{"key":"2021121022364937000_CIT0035","author":"Control ECfDPa. Vaccine schedules in all countries of the European Union"},{"key":"2021121022364937000_CIT0036","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1038\/s41598-017-01024-8","article-title":"Multidisciplinary study of the secondary immune response in grandparents re-exposed to chickenpox","volume":"7","author":"Ogunjimi","year":"2017","journal-title":"Sci Rep"},{"key":"2021121022364937000_CIT0037","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.07116","article-title":"Integrating between-host transmission and within-host immunity to analyze the impact of varicella vaccination on zoster","volume":"4","author":"Ogunjimi","year":"2015","journal-title":"eLife"},{"key":"2021121022364937000_CIT0038","doi-asserted-by":"crossref","first-page":"e5012","DOI":"10.7717\/peerj.5012","article-title":"Evaluation of the effect of chickenpox vaccination on shingles epidemiology using agent-based modeling","volume":"6","author":"Rafferty","year":"2018","journal-title":"PeerJ"},{"key":"2021121022364937000_CIT0039","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1016\/j.vaccine.2011.01.037","article-title":"Modelling the impact of a combined varicella and zoster vaccination programme on the epidemiology of varicella zoster virus in England","volume":"29","author":"van Hoek","year":"2011","journal-title":"Vaccine"},{"key":"2021121022364937000_CIT0040","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1080\/14760584.2019.1646129","article-title":"Do varicella vaccination programs change the epidemiology of herpes zoster? A comprehensive review, with focus on the United States","volume":"18","author":"Harpaz","year":"2019","journal-title":"Expert Rev Vaccines"},{"key":"2021121022364937000_CIT0041","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1097\/INF.0b013e3181a90b16","article-title":"The incidence and clinical characteristics of herpes zoster among children and adolescents after implementation of varicella vaccination","volume":"28","author":"Civen","year":"2009","journal-title":"Pediatr Infect Dis J"},{"key":"2021121022364937000_CIT0042","doi-asserted-by":"crossref","first-page":"ofv001","DOI":"10.1093\/ofid\/ofv001","article-title":"Trends in hospitalizations with primary varicella and herpes zoster during the prevaricella and initial postvaricella and herpes zoster vaccine eras, Connecticut, 1994\u20132012","volume":"2","author":"Humes","year":"2015","journal-title":"Open Forum Infect Dis"},{"key":"2021121022364937000_CIT0043","first-page":"e20182917","article-title":"Incidence of herpes zoster among children: 2003\u20132014","author":"Weinmann","year":"2019"},{"key":"2021121022364937000_CIT0044","first-page":"1766","article-title":"Current and future effects of varicella and herpes zoster vaccination in Germany\u2014insights from a mathematical model in a country with universal varicella vaccination","volume":"12","author":"Horn","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"2021121022364937000_CIT0045","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12916-017-0983-5","article-title":"Influence of demographic changes on the impact of vaccination against varicella and herpes zoster in Germany\u2014a mathematical modelling study","volume":"16","author":"Horn","year":"2018","journal-title":"BMC Med"},{"key":"2021121022364937000_CIT0046","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1086\/529043","article-title":"Primary vaccine failure after 1 dose of varicella vaccine in healthy children","volume":"197","author":"Michalik","year":"2008","journal-title":"J Infect Dis"},{"key":"2021121022364937000_CIT0047","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1097\/01.inf.0000219484.55858.a2","article-title":"Control of varicella: why is a two-dose schedule necessary?","volume":"25","author":"Arvin","year":"2006","journal-title":"Pediatr Infect Dis J"},{"key":"2021121022364937000_CIT0048","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1097\/01.inf.0000172901.29621.e9","article-title":"Dose-response study of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children","volume":"24","author":"Shinefield","year":"2005","journal-title":"Pediatr Infect Dis J"},{"key":"2021121022364937000_CIT0049","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1097\/01.inf.0000172902.25009.a1","article-title":"Evaluation of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children","volume":"24","author":"Shinefield","year":"2005","journal-title":"Pediatr Infect Dis J"},{"key":"2021121022364937000_CIT0050","doi-asserted-by":"crossref","first-page":"e1721","DOI":"10.1097\/MD.0000000000001721","article-title":"Combination measles-mumps-rubella-varicella vaccine in healthy children: a systematic review and meta-analysis of immunogenicity and safety","volume":"94","author":"Ma","year":"2015","journal-title":"Medicine (Baltimore)"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciaa1708\/38958248\/ciaa1708.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/73\/11\/e3617\/41607787\/ciaa1708.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/73\/11\/e3617\/41607787\/ciaa1708.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T22:38:42Z","timestamp":1639175922000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/73\/11\/e3617\/5973941"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,11]]},"references-count":50,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,11,11]]},"published-print":{"date-parts":[[2021,12,6]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciaa1708","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,12,1]]},"published":{"date-parts":[[2020,11,11]]}}}